Antidiabetic Agents

Multum Therapeutic Class Comparison, United States, 2018

Total Prescriptions in (2018)

Drug Name Total Prescriptions (2018) Percent Share
Metformin Hydrochloride 83,762,981 38.3%
Insulin Glargine 24,911,721 11.4%
Glipizide 17,549,602 8%
Insulin Aspart 12,146,569 5.5%
Glimepiride 11,405,689 5.2%
Sitagliptin Phosphate 9,813,528 4.5%
Insulin Lispro 8,512,588 3.9%
Insulin Detemir 6,593,849 3%
Pioglitazone 5,178,777 2.4%
Liraglutide 4,771,234 2.2%
Dulaglutide 4,223,559 1.9%
Metformin Hydrochloride; Sitagliptin Phosphate 3,991,205 1.8%
Linagliptin 3,390,521 1.5%
Insulin Degludec 3,226,388 1.5%
Canagliflozin 3,108,373 1.4%
Glyburide 2,841,094 1.3%
Insulin Human; Insulin Isophane Human 2,689,053 1.2%
Empagliflozin 2,649,792 1.2%
Dapagliflozin 2,304,573 1.1%
Insulin Isophane 1,747,835 0.8%
Exenatide 1,365,998 0.6%
Insulin Human 1,252,990 0.6%
Saxagliptin Hydrochloride 1,056,369 0.5%
Semaglutide 445,540 0.2%

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2008-2018. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 21.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

ICU Trials: Summarized critical care trials at your fingertips
 
©2020 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Nov 19, 2020
Back to Top
Top